Background/Aim: This study aimed to show the trend of neutrophil counts and frequency of
febrile neutropenia after changing pegfilgrastim from 3.6 mg to 1.8 mg. Patients and …

e20587 Background: We evaluated the safety and efficacy of a single fixed 6 mg dose of
pegfilgrastim (a pegylated version of filgrastim) per cycle of chemotherapy, compared with …

This combined, retrospective analysis compared once-per-chemotherapy-cycle
pegfilgrastim with daily Filgrastim in breast cancer patients undergoing myelosuppressive …

Results: One dose of pegfilgrastim per chemother-apy cycle was comparable to daily
subcutaneous injections of filgrastim with regard to all efficacy end points, including the …

Pegylation of a protein can improve not only its formulation properties, but also both its
pharmacokinetic and pharmacodynamic performance. Pegfilgrastim was made by linking a …

9110 Background: Pegfilgrastim reduces neutropenia risk in patients (pts) on cytotoxic
chemotherapy. A single 6 mg dose per chemotherapy cycle commonly causes bone pain …

Background Neutropenia is common in patients receiving myelotoxic chemotherapy.
Pegfilgrastim, a sustained-duration filgrastim is a once-per-cycle therapy for prophylactic …

Purpose A phase II, open-label, dose-finding, randomized study was performed to evaluate
the recommended dose of pegfilgrastim in Japanese breast cancer patients. Methods …

Background Pegfilgrastim has been used to control febrile neutropenia associated with
chemotherapy. However, some patients may experience a marked increase in neutrophils …

BACKGROUND: Pegfilgrastim is a colony-stimulating factor used 24 to 72 hours after
myelosuppressive chemotherapy to decrease the incidence of febrile neutropenia …